2019 Annual Meeting | C130 - Diagnostic Pearls in Myelitis: a Case-based Approach

Date Tuesday 05/07/19

Time 07:00 AM - 09:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eoin P. Flanagan, MBBCh, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants will recognize the critical importance of time to nadir in the evaluation of myelopathy. Laboratory testing will be emphasized including when to order neural autoantibodies (e.g., Aquaporin-4-IgG or Myelin-Oligodendrocyte-Glycoprotein-IgG), how to interpret cerebrospinal fluid testing, and how to recognize MRI patterns (length of lesion, gadolinium enhancement pattern) that can guide clinicians to the correct diagnosis. Finally, participants will understand the benefits (steroids and if needed PLEX in acute transverse myelitis) and pitfalls of treatments for myelopathy (empiric steroids can worsen dural arteriovenous fistula).

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM EDT	Introduction	Introduction to Diagnostic Pearls in Myelitis Eoin P. Flanagan, MBBCh, FAAN
07:05 AM - 07:40 AM EDT	Speaker	Diagnostic Pearls in Pediatric Myelitis Brenda L. Banwell, MD, FAAN
07:40 AM - 08:15 AM EDT	Speaker	Clinical and Laboratory Pearls and Pitfalls in the Diagnosis of Myelitis Nicholas L. Zalewski, MD
08:15 AM - 08:50 AM EDT	Speaker	Imaging Pearls in Myelitis and its Mimics Eoin P. Flanagan, MBBCh, FAAN
08:50 AM - 09:00 AM EDT	Speaker	Conclusions and Questions Eoin P. Flanagan, MBBCh, FAAN

Faculty Disclosures
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Nicholas L. Zalewski, MD	Dr. Zalewski has nothing to disclose.
Brenda L. Banwell, MD, FAAN	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.

��ɫ��

��ɫ��